[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epcam\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epcam":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100660442","phase-1-this-is-a-phase-11b-study-to-evaluate-the-safety-and-preliminary-antitumor-activity-of-ltz-232-in-participants-with-advancedmetastatic-colorectal-cancer-and-other-solid-tumors-100660442",false,"NCT07878988","This is a Phase 1\u002F1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced\u002FMetastatic Colorectal Cancer and Other Solid Tumors","A Phase 1\u002F1b, Muticenter Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced\u002FMetastatic Colorectal Cancer and Other Solid Tumors","Inclusion Criteria:\n\n* Advanced \u002Fmetastatic colorectal tumors that have failed standard treatments\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\n* Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1\n* Adequate organ function based on laboratory testing\n\nExclusion Criteria:\n\n* Active infection with hepatitis B or C\n* Uncontrolled CNS metastases\n* Active autoimmune disease\n* Clinically significant cardiovascular disease not adequately controlled with medication or impaired function\n* Previous treatment with EpCAM targeting agent\n* Pregnant or breast feeding\n* Non-colorectal active malignancy within 3 years that could interfere with study interpretation","ALL","18 Years",{"count":19,"type":20},152,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.",[26,27,28,29,30],"Colorectal Cancer","Advanced\u002FMetastatic Solid Tumor","Solid Tumor (Phase I)","EPCAM","Colon Cancer","RECRUITING","2026-10-30",{"date":34,"type":35},"2026-11-03","ACTUAL",{"date":37,"type":35},"2026-10-28",{"date":39,"type":20},"2031-12",{"name":41,"class":42},"LTZ Therapeutics, Inc.","INDUSTRY"]